Evidence map›Paper›PMID 40799473›Full record

ArticleBio-protocol2025

Luminal Cerebrovascular Proteomics.

Sophia M Shi, Carolyn R Bertozzi, Tony Wyss-Coray

Abstract read
In one paragraph

Article in Bio-protocol, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sophia M ShiDepartment of Chemistry, Stanford University, Stanford, CA, USA.
Carolyn R BertozziDepartment of Chemistry, Stanford University, Stanford, CA, USA.
Tony Wyss-CorayStanford Chemistry, Engineering & Medicine for Human Health (ChEM-H), Stanford University, Stanford, CA, USA.

Funding

Targeting the Cancer GlycocalyxR01CA227942 · NCI · STANFORD UNIVERSITY · PI Carolyn Bertozzi · 2019 to 2026
$3.6M
Targeting CD22 to Restore Brain Homeostasis in Alzheimer's DiseaseRF1AG064897 · NIA · STANFORD UNIVERSITY · PI WYSS-CORAY, TONY · 2019 to 2019
$2.9M
Molecular signature of parabiosisR01AG072255 · NIA · STANFORD UNIVERSITY · PI WYSS-CORAY, TONY · 2021 to 2025
$2.4M
NCI NIH HHS R01 CA227942NIA NIH HHS R01 AG072255NIA NIH HHS RF1 AG064897
6 · The paper itself

Abstract

Brain endothelial cells, which constitute the cerebrovasculature, form the first interface between the blood and brain and play essential roles in maintaining central nervous system (CNS) homeostasis. These cells exhibit strong apicobasal polarity, with distinct luminal and abluminal membrane compositions that crucially mediate compartmentalized functions of the vasculature. Existing transcriptomic and proteomic profiling techniques often lack the spatial resolution to discriminate between these membrane compartments, limiting insights into their distinct molecular compositions and functions. To overcome these limitations, we developed an in vivo proteomic strategy to selectively label and enrich luminal cerebrovascular proteins. In this approach, we perfuse a membrane-impermeable biotinylation reagent into the vasculature to covalently tag cell surface proteins exposed on the luminal side. This is followed by microvessel isolation and streptavidin-based enrichment of biotinylated proteins for downstream mass spectrometry analysis. Using this method, we robustly identified over 1,000 luminally localized proteins via standard liquid chromatography-tandem mass spectrometry (LC-MS/MS) techniques, achieving substantially improved enrichment of canonical luminal markers compared with conventional vascular proteomic approaches. Our method enables the generation of a high-confidence, compartment-resolved atlas of the luminal cerebrovascular proteome and offers a scalable platform for investigating endothelial surface biology in both healthy and disease contexts. Key features • Enables high-resolution proteomic profiling of the luminal surface of the brain vasculature in vivo. • Improves signal-to-noise ratio through an added microvessel isolation step, reducing nonspecific background. • Applied to uncover aging-related changes in luminal endothelial surface protein composition. • Adaptable for identifying therapeutic targets, transporters, signaling pathways, and disease-associated alterations in the luminal vascular environment across diverse biological contexts.

Indexed as

AgingBlood–brain barrierBrain endothelial cellsCNSLuminalNeurodegenerationProteomicsVasculature

Identifiers

PMID40799473
PMCPMC12337002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.